• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway.

作者信息

Akslen L A, Haldorsen T, Thoresen S O, Glattre E

机构信息

Department of Pathology, Gade Institute, University of Bergen, Norway.

出版信息

Cancer Res. 1991 Feb 15;51(4):1234-41.

PMID:1997164
Abstract

Survival and prognostic factors were studied in 2479 clinically presenting thyroid cancers (TC) reported from the entire Norwegian population from 1970 to 1985. Complete follow-up was obtained (median, 48 months), with information on causes of death. At the end of the observation period, 498 patients were reported to have died of TC, representing 69.7% of all deaths. Among 216 patients dying of other main causes, TC was considered to be a contributing cause of death in 80 cases (11.2%). Multivariate regression analysis of TC deaths showed no significant difference according to sex in any of the histological types. Age had a strong impact on survival, and for papillary carcinomas this effect was apparent after the age of 55 years. Marked differences were observed between various histological types, even between papillary and follicular carcinomas when interactions were included. Furthermore, tumor stage was a strong predictor of TC deaths, and a reduced survival was also found in patients with lymph node metastases. In conclusion, the importance of age, histological type, and tumor stage as major prognostic factors has been documented in this population-based study from Norway.

摘要

相似文献

1
Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway.
Cancer Res. 1991 Feb 15;51(4):1234-41.
2
Incidence of thyroid cancer in Norway 1970-1985. Population review on time trend, sex, age, histological type and tumour stage in 2625 cases.1970 - 1985年挪威甲状腺癌的发病率。对2625例病例的时间趋势、性别、年龄、组织学类型和肿瘤分期进行的人群回顾。
APMIS. 1990 Jun;98(6):549-58.
3
Surgical treatment of papillary and follicular thyroid carcinoma.乳头状和滤泡状甲状腺癌的外科治疗
Int Surg. 1996 Jan-Mar;81(1):61-6.
4
Gastric cancer: correlation between clinicopathological factors and survival of patients (III).胃癌:临床病理因素与患者生存率的相关性(III)
Rom J Morphol Embryol. 2009;50(3):369-79.
5
Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.上颌窦癌的治疗:1997年与1977年美国癌症联合委员会分期系统的比较
Cancer. 1999 Nov 1;86(9):1700-11.
6
Population-based outcomes for pediatric thyroid carcinoma.儿童甲状腺癌的基于人群的结局
Laryngoscope. 2005 Feb;115(2):337-40. doi: 10.1097/01.mlg.0000154743.71184.09.
7
[Prognostic factors influencing survival after surgical treatment of well differentiated thyroid cancer].[影响高分化甲状腺癌手术治疗后生存的预后因素]
Wiad Lek. 2004;57(9-10):431-7.
8
Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.甲状腺嗜酸性细胞肿瘤患者的预后因素
Cancer. 2003 Mar 1;97(5):1186-94. doi: 10.1002/cncr.11176.
9
"Just Another Statistic".“只是又一个统计数字”
Oncologist. 1998;3(3):III-IV.
10
[Mortality of patients with differentiated thyroid carcinoma in Norway. The influence of sex, age, tumor stage, histologic type and residence at the time of diagnosis].
Tidsskr Nor Laegeforen. 1989 Jun 10;109(16):1765-9.

引用本文的文献

1
Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study.亚洲国家甲状腺癌的生存率:一项系统评价和荟萃分析研究。
Endocrine. 2023 Nov;82(2):237-249. doi: 10.1007/s12020-023-03408-5. Epub 2023 Jun 3.
2
Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers.使用18F-FDG-PET/CT指标预测放射性碘难治性甲状腺癌的生存率。
Diagnostics (Basel). 2022 Sep 30;12(10):2381. doi: 10.3390/diagnostics12102381.
3
Survival and Death Causes in Thyroid Cancer in Taiwan: A Nationwide Case-Control Cohort Study.
台湾甲状腺癌的生存情况与死亡原因:一项全国性病例对照队列研究。
Cancers (Basel). 2021 Aug 5;13(16):3955. doi: 10.3390/cancers13163955.
4
Nature and outcome of malignant goiter: a revisit.恶性甲状腺肿的性质和结局:重新审视。
Pan Afr Med J. 2021 Feb 23;38:204. doi: 10.11604/pamj.2021.38.204.27503. eCollection 2021.
5
Aberrant Expression of Androgen Receptor Associated with High Cancer Risk and Extrathyroidal Extension in Papillary Thyroid Carcinoma.雄激素受体异常表达与甲状腺乳头状癌的高癌症风险及甲状腺外侵犯相关。
Cancers (Basel). 2020 Apr 29;12(5):1109. doi: 10.3390/cancers12051109.
6
Current trends in the features of male thyroid cancer: Retrospective evaluation of their prognostic value.男性甲状腺癌特征的当前趋势:对其预后价值的回顾性评估。
Medicine (Baltimore). 2019 May;98(19):e15559. doi: 10.1097/MD.0000000000015559.
7
BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.BRAF V600E 赋予男性甲状腺癌患者疾病特异性死亡风险。
J Clin Oncol. 2018 Sep 20;36(27):2787-2795. doi: 10.1200/JCO.2018.78.5097. Epub 2018 Aug 2.
8
Scoring System for Mortality in Patients Diagnosed with and Treated Surgically for Differentiated Thyroid Carcinoma with a 20-Year Follow-Up.接受手术治疗的分化型甲状腺癌患者死亡率评分系统:20年随访研究
PLoS One. 2015 Jun 26;10(6):e0128620. doi: 10.1371/journal.pone.0128620. eCollection 2015.
9
Association between MTHFR C677T polymorphism and thyroid cancer risk: a meta-analysis.亚甲基四氢叶酸还原酶(MTHFR)C677T基因多态性与甲状腺癌风险的关联:一项荟萃分析。
Tumour Biol. 2014 Aug;35(8):7707-12. doi: 10.1007/s13277-014-2038-2. Epub 2014 May 8.
10
Association of XRCC1 polymorphisms with thyroid cancer risk.XRCC1基因多态性与甲状腺癌风险的关联。
Tumour Biol. 2014 May;35(5):4791-7. doi: 10.1007/s13277-014-1629-2. Epub 2014 Jan 30.